FindTrial
Sign In

To develope and validate the prediction nomogram of urethral carcinoma recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion

To develope and validate the prediction nomogram of urethral carcinoma recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022080
Enrollment
Unknown
Registered
2019-03-23
Start date
2019-03-21
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

Recurrence group :radical cystectomy
Non-recurrence group:radical cystectomy

Sponsors

Department of Urology, ShengJing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Male, muscle invasive stage, and underwent RC combined with urinary diversion (cutaneous urinary diversion or Ileal conduit)

Exclusion criteria

Exclusion criteria: Patients who had urothelial carcinoma in either urethral prostatic part or bladder neck, and had upper tract urothelial carcinoma or the history of the upper tract urothelial carcinoma.

Design outcomes

Primary

MeasureTime frame
Recurrence of urethra;—

Countries

China

Contacts

Public ContactSong Bai

Department of Urology, ShengJing Hospital of China Medical University

baisongcmu@163.com+86 18940255568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026